Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

NCT05490472 is registered in ClinicalTrials.gov with Jacobio Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05490472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05490472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 20, 2022
Completion date
August 31, 2027
Enrollment
102 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

arid1a gene mutation, er+ breast cancer, small cell lung cancer, sclc, solid tumors, triple negative breast cancer, tnbc